Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America Health Care Conference 2026 on May 12, 2026 at 11:20 a.m. PT (2:20 p.m. ET) in Las Vegas. The presentation will be webcast live and available on the company's Investors site.

According to the company, a replay will be posted about one hour after the event and archived on the website for approximately one month. Neurocrine describes its business focus, FDA-approved products across neurology and endocrine indications, and a mid- to late-stage clinical pipeline.

News Market Reaction – NBIX

+0.74%

7 alerts

+0.74% Session close to close

+5.7% Peak in 17 hr 26 min

$13.58B Market Cap

0.0x Rel. Volume

In the May 5 session, NBIX gained 0.74%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.7% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on NBIX’s planned presentation at a major Bank of America healthcare confe...

Analysis

This announcement centers on NBIX’s planned presentation at a major Bank of America healthcare conference, continuing its active investor outreach. In the past months, the company paired similar visibility efforts with substantive updates, including acquisition expansion and positive clinical and real‑world data. Investors monitoring this name may focus on how management frames its portfolio strategy, integration of the Soleno acquisition, and progress across late‑stage programs highlighted in recent releases, alongside upcoming financial disclosures.

Key Figures

Conference time (PT): 11:20 a.m. Conference time (ET): 2:20 p.m. Conference date: May 12, 2026 +2 more

5 metrics

Conference time (PT) 11:20 a.m. Presentation time at Bank of America Health Care Conference 2026

Conference time (ET) 2:20 p.m. Corresponding Eastern Time for conference presentation

Conference date May 12, 2026 Scheduled date of Bank of America Health Care Conference presentation

Webcast replay delay approximately one hour Time after event when webcast replay becomes available

Replay archive duration approximately one month Length of time webcast replay will be available on website

Historical Context

5 past events · Latest: Apr 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 29	Clinical outcomes publication	Positive	+0.3%	Publication established clinically meaningful change threshold for TDIS with INGREZZA.
Apr 22	Phase 3 data update	Positive	-0.8%	Two-year CAHtalyst Adult data showing sustained GC dose reductions with CRENESSITY.
Apr 14	Earnings call scheduling	Neutral	+0.5%	Announcement of Q1 2026 financial results release and conference call timing.
Apr 14	Real-world data	Positive	+3.5%	Head-to-head claims analysis showing higher treatment persistence with INGREZZA vs AUSTEDO XR.
Apr 06	Acquisition announcement	Positive	+0.7%	Agreement to acquire Soleno Therapeutics to add VYKAT XR and expand portfolio.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamentally positive updates (clinical data, acquisition) have generally seen modest positive price reactions, with one notable divergence on strong Phase 3 data.

Recent Company History

Over the past month, NBIX has released several clinically and strategically important updates. On Apr 6, the company announced a $2.9 billion Soleno acquisition to expand its endocrinology and rare disease portfolio, followed by real‑world data on INGREZZA on Apr 14 and a Q1 2026 results call scheduling the same day. Subsequent Phase 3 CRENESSITY data on Apr 22 and a tardive dyskinesia outcomes publication on Apr 29 highlighted clinical depth. Today’s Bank of America conference participation fits an ongoing pattern of active investor and scientific engagement.

Key Terms

biopharmaceutical, tardive dyskinesia, congenital adrenal hyperplasia, endometriosis, +2 more

6 terms

biopharmaceutical medical

"Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

tardive dyskinesia medical

"includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease"

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

congenital adrenal hyperplasia medical

"classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline"

Congenital adrenal hyperplasia is a group of inherited disorders in which the adrenal glands lack an enzyme needed to make certain hormones, causing a chronic imbalance of cortisol, aldosterone and/or sex hormones. Think of it as a factory assembly line missing a key part, so the body overproduces some products and underproduces others, requiring lifelong monitoring or hormone treatment. For investors, it matters because diagnosis, ongoing therapy, newborn screening and potential new drugs or gene therapies can drive medical spending, regulatory approvals and market opportunity in endocrinology and rare disease care.

endometriosis medical

"treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids"

Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility problems. It can impact a person's health and quality of life, potentially leading to increased healthcare costs and affecting workforce productivity. For investors, understanding conditions like endometriosis highlights the importance of healthcare innovations and markets related to women's health.

uterine fibroids medical

"classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline"

Uterine fibroids are noncancerous growths that develop in the muscular wall of the uterus, often described like small rubbery lumps within the organ. They matter to investors because they affect a large number of people of reproductive age and drive demand for diagnostics, medications, minimally invasive procedures and surgical devices, creating revenue opportunities and regulatory, reimbursement and competitive considerations for healthcare companies.

clinical development medical

"a robust pipeline including multiple compounds in mid- to late-phase clinical development across"

Clinical development is the process of testing a medical treatment in people to prove it is safe and works, moving from small early safety checks to larger trials that measure benefit and side effects. For investors it matters because each successful step reduces uncertainty and brings a product closer to regulatory approval and sales—like moving a prototype through road tests before mass production—while failures or delays can dramatically cut expected value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the Bank of America Health Care Conference 2026 at 11:20 a.m. Pacific Time (2:20 p.m Eastern Time) on May 12, 2026 in Las Vegas.

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)  

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-bank-of-america-health-care-conference-2026-302762661.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences (NBIX) present at the Bank of America Health Care Conference 2026?

Neurocrine will present on May 12, 2026 at 11:20 a.m. PT (2:20 p.m. ET). According to the company, the session takes place in Las Vegas and the timing is confirmed for that date and time.

How can investors watch the NBIX presentation at the Bank of America Health Care Conference 2026?

Investors can watch via a live webcast on Neurocrine's Investors website. According to the company, the webcast link is posted on neurocrine.com and will stream the live presentation.

Will Neurocrine (NBIX) provide a replay of its Bank of America Health Care Conference presentation?

Yes. According to the company, a replay will be available about one hour after the presentation concludes. The replay will be archived on the investor site for approximately one month.

What topics will Neurocrine Biosciences (NBIX) likely cover in its Bank of America conference presentation?

The presentation will cover company strategy, approved products and pipeline updates. According to the company, executives will discuss FDA-approved treatments, mid- to late-stage clinical programs and the firm's therapeutic focus areas.

Where can I find additional investor resources and company information for Neurocrine (NBIX)?

Company information and investor resources are available on Neurocrine's website and social channels. According to the company, visit neurocrine.com and follow LinkedIn, X, Facebook and YouTube for updates and materials.